The device could help a million people with a severe form of macular degeneration to be able to see enough to read.

Welcome to Wrinkles Week on the Strategist, where we’re deeply vetting skin-care solutions for anyone who’s looking to smooth ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Diana Do, MD, a professor of ophthalmology and vice chair of Clinical Affairs at Stanford University's Byers Eye Institute, presented research on aflibercept 8 mg in treating neovascular age-related ...

The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp , giving patients a less painful and more convenient option to treat a progressive condition that can severely ...

Presenters at the AAO discussed phase 2 clinical trial results evaluating the safety and efficacy of foselutoclax (UBX1325) compared with aflibercept in diabetic macular edema.